Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Neoplasia (New York, N.Y.)|January 10, 2014
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor modelsThomas O'Brien, Jason Oeh, Yang Xiao, et al.
Plos One|October 7, 2014
Structural basis for resistance to diverse classes of NAMPT inhibitorsWeiru Wang, Kristi Elkins, Angela Oh, et al.
Annals of Hematology|April 30, 2022
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromesMikkael A Sekeres, Michael Schuster, Magalie Joris, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 16, 2014
Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferaseTanja S Zabka, Jatinder Singh, Preeti Dhawan, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2013
Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Kenneth W Bair, Timm Baumeister, et al.
Journal of Medicinal Chemistry|August 20, 2016
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) InhibitorsMark Zak, Po-Wai Yuen, Xiongcai Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 29, 2015
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitorsAnneleen Daemen, David Peterson, Nisebita Sahu, et al.
Leukemia|August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trialMikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
The Journal of Biological Chemistry|August 31, 2018
Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolismMaša Ždralević, Almut Brand, Lorenza Di Ianni, et al.
Pageof 8